Indolent Lymphoma - Pipeline Review, H2 2013

Indolent Lymphoma - Pipeline Review, H2 2013

Oct 2013 Global Markets Direct Lymphoma92 Pages Price :
$ 2000

Global Markets Directs, \'Indolent Lymphoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. Indolent Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Indolent Lymphoma.
  • A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Indolent Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Indolent Lymphoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Indolent Lymphoma 8
Indolent Lymphoma Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Indolent Lymphoma Therapeutics - Products under Development by Companies 15
Companies Involved in Indolent Lymphoma Therapeutics Development 16
F. Hoffmann-La Roche Ltd. 16
Biogen Idec Inc. 17
Amgen Inc. 18
Sanofi-Aventis 19
Gilead Sciences, Inc. 20
Infinity Pharmaceuticals, Inc. 21
Astellas Pharma Inc. 22
Cell Therapeutics, Inc. 23
Sandoz Inc. 24
Bayer AG 25
Incyte Corporation 26
Merck KGaA 27
Accentia Biopharmaceuticals, Inc. 28
Biothera 29
Indolent Lymphoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 36
bendamustine hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
obinutuzumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
pacritinib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SAR-245409 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
dasiprotimut T - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
idelalisib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DI-B4 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BAY-806946 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
rituximab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
duvelisib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
rituximab biosimilar - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GS-9973 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
INCB-047986 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Indolent Lymphoma Therapeutics - Drug Profile Updates 59
Indolent Lymphoma Therapeutics - Dormant Products 80
Indolent Lymphoma - Product Development Milestones 81
Featured News & Press Releases 81
Feb 20, 2013: Mundipharma Reports Publication Of Phase III Data Of Bendamustine Plus Rituximab In Lancet 81
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 82
Dec 03, 2012: Mundipharma Announces Acceptance Of Bendamustine Abstracts At Annual Meeting Of American Society Of Hematology 83
Aug 17, 2011: Emergent Announces Initiation Of Phase Ib/II Study Of TRU-016 In Combination With Rituximab And Bendamustine In Subjects With Relapsed-Indolent Lymphoma 84
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin\'s Lymphomas At ASH 85
Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies 86
Dec 05, 2010: Calistoga Reports Positive Results From CAL-101 Phase I Trial In Hematologic Malignancies 87
Jun 14, 2010: Calistoga Pharmaceuticals Presents Preclinical And Clinical Data Supporting Benefit Of First In Class, Novel Mechanism Of CAL-101, An Oral Delta Isoform-Selective PI3 Kinase Inhibitor 89

Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Table


Number of Products Under Development for Indolent Lymphoma, H2 2013 8
Products under Development for Indolent Lymphoma - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
F. Hoffmann-La Roche Ltd., H2 2013 16
Biogen Idec Inc., H2 2013 17
Amgen Inc., H2 2013 18
Sanofi-Aventis, H2 2013 19
Gilead Sciences, Inc., H2 2013 20
Infinity Pharmaceuticals, Inc., H2 2013 21
Astellas Pharma Inc., H2 2013 22
Cell Therapeutics, Inc., H2 2013 23
Sandoz Inc., H2 2013 24
Bayer AG, H2 2013 25
Incyte Corporation, H2 2013 26
Merck KGaA, H2 2013 27
Accentia Biopharmaceuticals, Inc., H2 2013 28
Biothera, H2 2013 29
Assessment by Monotherapy Products, H2 2013 30
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Stage and Molecule Type, H2 2013 35
Indolent Lymphoma Therapeutics - Drug Profile Updates 59
Indolent Lymphoma Therapeutics - Dormant Products 80

List of Chart


Number of Products under Development for Indolent Lymphoma, H2 2013 8
Products under Development for Indolent Lymphoma - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Late Stage Products, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 30
Assessment by Route of Administration, H2 2013 31
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Molecule Type, H2 2013 33
Assessment by Stage and Molecule Type, H2 2013 34

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top